Vascarta has pursued intellectual property protection for its key assets.

The Vascarta technology platform is based on a proprietary formulation with broad applications  in transdermal drug delivery and blood storage and transfusion. U.S. Patent No. 12,059,493 and  pending U.S. Patent Application No. 18/051,266 cover the formulation, which includes an  effective amount of a nitric oxide (NO) booster such as a curcuminoid or flavonoid dissolved in a  polyol solvent. 

U.S. Patent No. 11,786,456, along with U.S. Patent Application Nos. 18/487,668 and 18/794,030,  are directed to methods of treating various diseases and conditions using the formulation. These  conditions include renal failure, hypertension, stroke, microemboli, open wounds, sexual and  bladder dysfunction, sickle cell disease, pain, inflammation, osteoarthritis, rheumatoid arthritis,  endothelial dysfunction, dermatological and ophthalmological conditions, bacterial and viral  infections, ischemia-reperfusion injury, hypoxia-reoxygenation injury, cytokine storm, cerebral  malaria, Chagas disease, hemoglobinopathies, type 2 diabetes, neurodegenerative disorders, lupus,  long COVID, and vascular leakage. 

The formulation is also applicable to blood storage and transfusion. U.S. Patent No. 12,151,019  covers a method for preparing a blood sample with reduced red blood cell lesion ex vivo, as well  as the treated blood sample itself and a method for transfusing it into a subject in need. Divisional  U.S. Patent Application No. 18/944,844 is directed to an ex vivo biological material sample  comprising a biological material admixed with the formulation. It also includes claims to methods  of transfusing the blood and treating disease via administration of the treated biological material  sample. 

Corresponding patent applications covering the formulation and its medical and transfusion related uses have been filed in foreign jurisdictions, including Australia, Brazil, Canada, China,  Europe, India, Mexico, Nigeria, Japan, and Korea. 

The Vascarta patent portfolio offers robust, multi-layered protection that significantly limits  competitors’ ability to develop copycat products. The formulation patents claim the specific  combination of a nitric oxide (NO) booster in a polyol solvent, making it difficult to replicate the  functional properties without infringing. This protection is further reinforced by method patents  covering a wide range of therapeutic and transfusion-related applications, from chronic diseases  to acute clinical conditions. By securing rights across formulations, methods of treatment, and  methods of use, the portfolio establishes strong legal barriers against unauthorized use. As a result,  any attempt to imitate the formulation or its applications can be effectively challenged and  enforced under patent laws. Exclusive license rights to a novel method for making existing cancer therapies safer and more effective through unique and complementary mechanisms of action via unique linker chemistry.